New strategies in the determination of fibrin and fibrin(ogen) derivatives by monoclonal antibodies.
Until recently only tests with a limited specificity were available for the assessment of the products of activated coagulation and/or fibrinolysis. Those assays were based on polyclonal antibodies, which crossreact with fibrinogen, and as a consequence they were performed on serum samples i.e. after removal of fibrinogen by clotting. Serum preparation, however, is a notorious source of artefactually high or low levels of fibrin(ogen) degradation products, and is not suitable for the determination of coagulation products. Recently, highly specific monoclonal antibodies (MoAb's) have been developed, the majority of which do not crossreact with fibrinogen. This has enabled new strategies to be developed, i.e. assays using these MoAb's on plasma samples. Furthermore, the new assays can discriminate between (individual) fibrin and fibrinogen degradation products, and coagulation products can be assessed in the same plasma samples.
Nieuwenhuizen
W
W
Gaubius Institute Netherlands Organization for Applied Scientific Research, Leiden, The Netherlands.
D000911:Antibodies, Monoclonal; D001777:Blood Coagulation; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis* / Q000276:immunology; D005342:Fibrinolysis; D006801:Humans; D007124:Immunoenzyme Techniques; D007841:Latex Fixation Tests
D000911:Antibodies, Monoclonal; D005338:Fibrin Fibrinogen Degradation Products